Zimmer Biomet Q3 sales up 4.1% cc; lowers FY2024 guidance

ZIMMER BIOMET HOLDINGS, INC.

2024-Q3 EPS reported $3.24 revenue$5,655,400,000

Q3 net sales $1.824B (+4.1% cc); diluted EPS $1.23, adjusted EPS $1.74.
FY2024 constant currency revenue growth guidance narrowed to 4.25%-4.75% from 5.0%-6.0%.
FY2024 adjusted diluted EPS guidance lowered to $7.95-$8.05 from $8.00-$8.15.
CEO Ivan Tornos cited ERP implementation challenges as headwind to full-year performance.
Completed acquisition of OrthoGrid Systems (AI hip guidance); launched Z1 Femoral Hip System.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.